Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Purkinje neuron Ca2+ influx reduction rescues ataxia in SCA28 model
Francesca Maltecca, … , Angelo Quattrini, Giorgio Casari
Francesca Maltecca, … , Angelo Quattrini, Giorgio Casari
Published December 8, 2014
Citation Information: J Clin Invest. 2015;125(1):263-274. https://doi.org/10.1172/JCI74770.
View: Text | PDF
Research Article Neuroscience

Purkinje neuron Ca2+ influx reduction rescues ataxia in SCA28 model

  • Text
  • PDF
Abstract

Spinocerebellar ataxia type 28 (SCA28) is a neurodegenerative disease caused by mutations of the mitochondrial protease AFG3L2. The SCA28 mouse model, which is haploinsufficient for Afg3l2, exhibits a progressive decline in motor function and displays dark degeneration of Purkinje cells (PC-DCD) of mitochondrial origin. Here, we determined that mitochondria in cultured Afg3l2-deficient PCs ineffectively buffer evoked Ca2+ peaks, resulting in enhanced cytoplasmic Ca2+ concentrations, which subsequently triggers PC-DCD. This Ca2+-handling defect is the result of negative synergism between mitochondrial depolarization and altered organelle trafficking to PC dendrites in Afg3l2-mutant cells. In SCA28 mice, partial genetic silencing of the metabotropic glutamate receptor mGluR1 decreased Ca2+ influx in PCs and reversed the ataxic phenotype. Moreover, administration of the β-lactam antibiotic ceftriaxone, which promotes synaptic glutamate clearance, thereby reducing Ca2+ influx, improved ataxia-associated phenotypes in SCA28 mice when given either prior to or after symptom onset. Together, the results of this study indicate that ineffective mitochondrial Ca2+ handling in PCs underlies SCA28 pathogenesis and suggest that strategies that lower glutamate stimulation of PCs should be further explored as a potential treatment for SCA28 patients.

Authors

Francesca Maltecca, Elisa Baseggio, Francesco Consolato, Davide Mazza, Paola Podini, Samuel M. Young Jr., Ilaria Drago, Ben A. Bahr, Aldamaria Puliti, Franca Codazzi, Angelo Quattrini, Giorgio Casari

×

Figure 6

Presymptomatic treatment with ceftriaxone rescues both motor symptoms and PC-DCD in SCA28 mice.

Options: View larger image (or click on image) Download as PowerPoint
Presymptomatic treatment with ceftriaxone rescues both motor symptoms an...
(A) Beam-walking test performed on Afg3l2+/– and WT mice treated with vehicle or ceftriaxone at presymptomatic stages. Data represent the mean ± SD of 4 independent tests; n = 15. *P < 0.05 and **P < 0.001 by Student’s t test. (B) Semithin (upper panels) and cryostat-cut sections (lower panels) of cerebellum from ceftriaxone-treated versus vehicle-treated Afg3l2+/– and WT mice at 8 months of age stained with toluidine blue and anti-calbindin Abs, respectively. Arrows indicate dark PCs. Scale bars: 100 μm. (C) Quantification of healthy and dark PCs in ceftriaxone-treated versus vehicle-treated Afg3l2+/– mice. Data represent the mean ± SD; n = 4. P < 0.001 by Student’s t test for both healthy (*) and dark (§) PCs. (D) WB analysis of cerebellar extracts from Afg3l2+/– and WT mice treated with vehicle or ceftriaxone using anti-spectrin Ab. A control cerebellar extract treated with 2 mM CaCl2 and 1 U calpain was used as a positive control. (E) Beam-walking test performed on Afg3l2+/– mice and their littermates at postsymptomatic stages (8 months) and after ceftriaxone treatment. Data represent the mean ± SD of 4 independent tests; n = 15. *P < 0.05 and **P < 0.001 by Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts